Actively Recruiting
Study of First-Line Immunotherapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Observing Real-World Treatment Patterns and Outcomes
Led by Peking University People's Hospital · Updated on 2025-12-22
500
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in patients with newly diagnosed multiple myeloma NDMM in China. This study aims to leverage a large patient resource to establish an NDMM patient cohort and provide essential evidence for optimizing individualized treatment and improving patient prognosis. The study is sponsored by Peking University Peoples Hospital and involves following patients over time to understand disease characteristics and treatment effects. Participants will receive first-line immunotherapy treatments, which may include proteasome inhibitors, immunomodulatory drugs, or anti-CD38 monoclonal antibodies, either alone or in combination with other therapies. The study will monitor treatment patterns and responses from July 2025 to July 2026, with additional follow-up through July 2027 to assess minimal residual disease and other clinical markers. Treatments are provided as part of usual care, and the study collects data without altering therapy. During participation, researchers will collect data on disease features, treatment types, and clinical outcomes using medical records and follow-ups over one year, with extended monitoring for survival and causes of death. Outcome measures include real-world overall response rate, disease staging, serum markers, and genetic abnormalities. The study involves no experimental treatments but focuses on observing current treatment use and outcomes. The total follow-up period extends up to two years to capture long-term patient status.
CONDITIONS
Brief Title
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
Research Team
P
Prof. LIU, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here